Exact Sciences (EXAS) Tops Q2 EPS by 25c, provides guidance

Exact Sciences (NASDAQ: EXAS) reported Q2 EPS of ($0.09), $0.25 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $699.26 million versus the consensus estimate of $690.01 million.

GUIDANCE:

Exact Sciences sees FY2024 revenue of $2.81-2.85 billion, versus the consensus of $2.83 billion.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Elastic N.V. (ESTC) Tops Q1 EPS by 12c, Beats on Revenue; offers FY27 Guidance
• Trinity Biotech faces Nasdaq delisting risk over market value